BLA 761053 · Genentech INC
Ocrevus
Ocrelizumab · Injection · CD20-directed Cytolytic Antibody
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Mar 28, 2017
Approved uses
3
Original approval plus efficacy supplements
Registered trials
89
45 Phase 3, 24 recruiting
FAERS reports
62,729
31,724 serious, 1,540 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 14, 2026.
OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more. OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults ( 1 ) Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more ( 1 )
Mechanism: The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 8, 2026 Supplement 38 · Efficacy · priority review LabelLetterMedication Guide
- Dec 14, 2020 Supplement 22 · Efficacy LabelLetter
- Mar 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
- OCREVUS · OCRELIZUMAB 30MG/1ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ocrelizumab" as an intervention, any sponsor and status, largest first.
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05269004 · 1,300 participants (planned) · Start May 3, 2022 · Primary completion Dec 31, 2027
Drug: Ocrelizumab · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Laguna Hills, California; Palo Alto, California · 232 sites in all
- Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03085810 · 1,225 participants · Start Mar 24, 2017 · Primary completion Apr 27, 2023
Drug: Ocrelizumab · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Irvine, California; Sunnyvale, California; Aurora, Colorado · 193 sites in all
- This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03599245 · 1,055 participants · Start Jul 12, 2018 · Primary completion Jul 17, 2025
Drug: Ocrelizumab · For: Multiple Sclerosis
Sites: Buenos Aires, Argentina; Ciudad Autonoma Buenos Aires, Argentina; Rosario, Argentina · 161 sites in all
- A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)Pivotal-lookingTerminated
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00406419 · 1,015 participants · Start Dec 27, 2006 · Primary completion Oct 6, 2009
Drug: Methotrexate; ocrelizumab and 1 more · For: Rheumatoid Arthritis
Sites: South San Francisco, California
- A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04035005 · 1,013 participants · Start Aug 12, 2019 · Primary completion Jan 15, 2025
Drug: Ocrelizumab; Placebo · For: Multiple Sclerosis, Primary Progressive
Sites: Washington D.C., District of Columbia; Clearwater, Florida; Orlando, Florida · 153 sites in all
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04544449 · 985 participants · Start Oct 26, 2020 · Primary completion Sep 17, 2025
Drug: Fenebrutinib; Ocrelizumab and 2 more · For: Multiple Sclerosis, Primary Progressive
Sites: Homewood, Alabama; Berkeley, California; Fullerton, California · 190 sites in all
- A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03523858 · 927 participants · Start May 28, 2018 · Primary completion Oct 22, 2026
Drug: Ocrelizumab · For: Progressive Multiple Sclerosis (PMS)
Sites: Laguna Hills, California; Pasadena, California; San Francisco, California · 120 sites in all
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04544436 · 864 participants · Start Nov 26, 2020 · Primary completion Dec 19, 2024
Drug: Ocrelizumab; Ocrelizumab and 2 more · For: Multiple Sclerosis
Sites: Cullman, Alabama; Homewood, Alabama; Phoenix, Arizona · 121 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- covid-1911,587
- fatigue6,297
- urinary tract infection3,818
- headache3,311
- multiple sclerosis3,123
- multiple sclerosis relapse2,818
- gait disturbance2,756
- asthenia2,735
- nasopharyngitis2,601
- pain2,585
- fall2,559
- drug ineffective2,491
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 10 |
| 2011 | 13 |
| 2012 | 17 |
| 2013 | 7 |
| 2014 | 12 |
| 2015 | 10 |
| 2016 | 30 |
| 2017 | 1,129 |
| 2018 | 4,995 |
| 2019 | 6,275 |
| 2020 | 5,549 |
| 2021 | 7,193 |
| 2022 | 11,405 |
| 2023 | 8,927 |
| 2024 | 9,566 |
| 2025 | 4,551 |
| 2026 | 3,037 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ocrevus (Ocrelizumab)
2024 spending
$195M
Beneficiaries
3,085
5,163 claims
Per beneficiary
$63,231
$1,932.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $81,042,687 |
| 2021 | $96,636,442 |
| 2022 | $123,045,548 |
| 2023 | $157,049,386 |
| 2024 | $195,066,362 |
Part B: Ocrevus (Ocrelizumab) · HCPCS J2350
2024 spending
$669M
Beneficiaries
11,764
20,976 claims
Per beneficiary
$56,845
2024 ASP limit $59.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $618,776,537 |
| 2021 | $608,203,407 |
| 2022 | $693,652,844 |
| 2023 | $697,178,191 |
| 2024 | $668,719,044 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA, Drudge C, Walsh S, et al. · J Comp Eff Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Furie RA, Aroca G, Cascino MD, et al. · Ann Rheum Dis 2022 · Multicenter Study, Randomized Controlled Trial
- Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.
Montalban X, Matthews PM, Simpson A, et al. · Ann Clin Transl Neurol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
Newsome SD, Krzystanek E, Selmaj KW, et al. · Neurology 2025 · Clinical Trial, Phase III, Equivalence Trial
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.